Skip to main content

Table 2 Univariate analysis of prognostic factors for overall survival and progression-free survival

From: Improved clinical outcome using transarterial chemoembolization combined with radiofrequency ablation for patients in Barcelona clinic liver cancer stage A or B hepatocellular carcinoma regardless of tumor size: results of a single-center retrospective case control study

Factor OS   PFS
HR P Value   HR P Value
Sex (female vs. male) 1.091 0.576   1.051 0.78
Age 1.008 0.162   1.004 0.489
Mean tumor diameter (cm) 1.102 < 0.001   1.119 < 0.001
Albumin g/dL 0.987 0.265   0.995 0.667
Total bilirubin u mol/L 1.004 0.002   1.002 0.139
AFP > 400 ng/mL 1.868 < 0.001   1.941 < 0.001
Child-Pugh B 0.847 0.445   0.833 0.437
BCLC B 2.072 < 0.001   2.631 < 0.001
Hepatitis B 1.589 0.118   1.203 0.534
TACE-RFA 0.205 0   0.147 0
Number of tumors 1.089 0.446   1.089 0.488
  1. OS overall survival, PFS progression-free survival, HR hazard ratio, AFP alpha-fetoprotein, BCLC Barcelona Clinic Liver Cancer, RFA radiofrequency ablation, TACE transarterial chemoembolization